The association between urine amylase levels and the development of post-operative complications after Whipple resection is still unknown. The aim of this study was to determine the prognostic value of urine amylase levels for post-operative complications in patients who underwent Whipple resection. In this retrospective-prospective cohort study we analyzed amylase levels in urine, serum, and drains in 52 patients who underwent Whipple resection preoperatively and on Post-operative Day 1 (POD1) after the intervention. Patients were followed up for 3 months to assess their predictive value for post-operative complications. In patients with complications, urine amylase levels were significantly higher on POD1 than before resection (198.89 ± 28.41 vs. 53.70 ± 7.44, p=0.000). Considering the sensitivity and specificity of the urine amylase level on POD1, an area under the ROC curve of 0.918 was obtained (p<0.001, 95% Confidence interval [CI]: 0.894-0.942). Patients with urine amylase levels ≥140.00 U/L had significantly higher risks of post-operative pancreatic fistula (POPF) grade C (definition of POPF done according to the ISGP) (RR:20.26; 95% CI: 1.18-347.07; p=0.038), readmission to hospital (RR: 6.61; 95% CI: 1.53-28.58; p=0.011), reoperation (RR: 5.67; 95% CI: 1.27-25.27; p=0.023), and mortality (RR:17.00; 95% CI: 2.33-123.80; p=0.005) than patients with urine amylase levels <140.00 U/L. Urine amylase levels on POD1 displayed strong and significant positive correlations with serum amylase levels (r=0.92, p=0.001) and amylase levels in drains (r=0.86, p=0.002). We can conclude that urine amylase levels on POD1 have good prognostic value for post-operative complications after Whipple resection and might be used as an additional predictive risk factor.
ABSTRACT Objectives: To examine a relationship between protein C (PC) and antithrombin III (AT III) activities with ejection fraction of left ventricle (EFLV), in the early phase of acute ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI), and to investigate whether PC and AT III are associated with major adverse cardiovascular events (MACE) within 6 months following from pPCI. Patients and methods: The research had a prospective character and included 357 patients who had, following the diagnosis of the STEMI, undergone pPCI at the Clinic of Cardiology and Emergency Internal Medicine, Military Medical Academy, Belgrade, Serbia, from January 2010 until April 2019. Results: The EFLV positively correlated with PC values (rho = 0.229). There was a statistically significant increase in the PC values between patients with MACE compared with those without MACE at 6 months’ follow-up evaluation (p < 0.0001). Also, significant difference in PC values between patients who died in hospital and those who were alive at 6 months’ follow-up (p < 0.01) was observed. PC values were different across different EFLV groups (p < 0.001), increasing from the 1st to the 4th EFLV quartiles: the median and the interquartile values for the 1st, 2nd, 3rd and 4th quartiles were 1.0400IU/l ± 0.15, 1.1400IU/l ± 0.15, 1.1350IU/l ± 0.16 and 1.2200IU/l ± 0.14, respectively. Conclusion: Increased PC activity in the early phase of STEMI is associated with higher EFLV 5 days after the pPCI as well as with MACE at 6 months after the pPCI.
Introduction: Osteoporosis is a chronic progressive bone disease where the bone tissue resorption exceeds its regenerative capacities. Such a process leads to the reduction of bone mineral density (BMD), and distortion of trabecular microarchitectonics, which creates the basis for an increased fracture risk on a “low trauma” for osteoporosis patients. The notion of low trauma implies a stressor that will not cause a fracture in a healthy person under normal circumstances. BMD is a strong predictor of future fractures. However, many fractures occur in persons with BMD values beyond the defined osteoporosis threshold, and BMD measurement only partially identifies the part of the population with increased fracture risk. Also, it is known that risk factors are influencing the bone mass reduction as predictors of future fractures, and their association may lead to an increased fracture risk irrespective of the bone mass and T-score. Aim: The 10-year individual risk assessment for osteoporotic fracture and the analysis of impact of individual and multiple osteoporosis risk factors on the degree of osteoporotic fracture risk. Methods: The research is a retrospective-prospective study which analyzed 120 patients divided into two groups: 1) asymptomatic patients with known risk factors for osteoporosis in the age group of 40-65 (n=60), 2) asymptomatic patients with known risk factors for osteoporosis in the age group of 65-90 (n=60). FRAX® algorithm was used as a tool for the 10-year hip fracture risk assessment, with prior approval of the Centre for Metabolic Bone Diseases, University of Sheffield from the United Kingdom. Fracture risk assessment was calculated using the online FRAX® calculator. High risk is defined as the hip fracture risk higher than 3% or the risk of a “big” osteoporotic fracture higher than 20%. Results are expressed as mean values with a standard deviation. A comparison between tested patient groups was made applying the student T-test. Results: 32% of patients of average age of 65.8±12.6 years are under high hip fracture risk, 28% of patients are under the hip fracture risk higher than 3%, and the risk for 0.03% patients is higher than 20%. Patients with high fracture risk are of advanced age, female, with lower body weight and height values, lower bone mineral density (BMD) and T score values than patients who are not under a high fracture risk. A positive family anamnesis to osteoporosis and fractures, earlier fractures, smoking, rheumatoid arthritis, and use of glucocorticoids are risk factors that are more represented in patients with high fracture risk and osteoporosis. The impact of the majority of individual risk factors for osteoporosis and fracture is moderate, and their joint effect is significant. The contribution of individual risk factors to the overall 10-year fracture risk depends on the type, number and association of risk factors. Conclusion: This research is a contribution to the resolution of polemics among authors, i.e. a dilemma whether persons with multiple clinical risk factors for osteoporosis with T score values beyond the defined threshold for osteoporosis are candidates for therapy with bisphosphonates, and a dilemma whether persons without any clinical risk factors for osteoporosis with T score values within the defined osteoporosis threshold require therapy with bisphosphonates, or only monitoring is sufficient.
Objectives: To assess the prognostic value of pentraxin 3 (PTX3) in patients with ST-elevation myocardial infarction (STEMI) after bare-metal stent (BMS) implantation. Methods: In this prospective study, PTX3, interleukin (IL-6), IL-10, high-sensitivity c-reactive protein (hsCRP), and cardiac troponin I (cTnI) plasma values were determined before and 24hours after BMS implantation in 97 consecutively enrolled patients with STEMI who were admitted to University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina between February 2016 and February 2017. Patients were followed for 24 months to assess major adverse cardiovascular events (MACEs). Results: At 24 hours after percutaneous coronary intervention (PCI), plasma values of PTX3, IL-6, hsCRP, and cTnI were significantly increased; and IL-10 levels were significantly decreased compared with the values determined before PCI. Patients with MACEs had significantly higher plasma PTX3 levels at 24 hours after BMS-PCI than in patients without MACEs. Patients with PTX3 plasma values ≥5042 ng/ml had a significantly higher risk of MACEs than patients with PTX3 levels <5.042 ng/mL. Pentraxin 3 levels exhibited strong and significant correlations with IL-6 and IL-10 levels. Pentraxin 3, cTnI, and IL-6, but not hsCRP levels have showed independent association with MACEs, according to the multivariate Cox regression analysis. Conclusion: Pentraxin 3 might be better serum prognostic marker than IL-6, IL-10 or high sensitivity CRP for MACEs after BMS-PCI. It might help to make better risk stratification of those patients who are undergoing BMS-PCI.
Introduction: Metabolic syndrome (METS) represent a simultaneous presence of multiple metabolic disorders in one person. Prevalence is increasing worldwide, which is probably related to increased obesity and sedentary lifestyle. Non-alcoholic steatosis or “fatty liver” is a metabolic disease caused by fat dysfunction. It can be a sign of some other disease, and can often be found in patients with metabolic disorders. Ultrasound is an acceptable method for the identification of fatty steatosis. There is evidence that when turmeric is used as a herbal diet, with its active metabolite of curcumin, can repair fatty acidosis and thus prevent progression of fatty steatosis complications such as cirrhosis and liver cancer. Goal. The aim of the study was to determine the effects of 400 mg curcuminaddition to the nutrition on ultrasound morphological characteristics of the liver in METS patients. Methodology: A prospective cohort study was conducted on 100 subjects with METS, treated in the family medicine practice of the Tuzla Canton, aged 35-70 years. The therapeutic effects of 400 mg curcumin on ultrasound-morphological characteristics of the liver were followed, validated by ultrasound in 50 respondents of experimental groups with METS. The data were processed by the IBM SPSS Statistics 21 statistical analysis program using parametric techniques andStudent’s t-test for paired samples. Results: There were 65% of women in the study. There were no statistically significant differences in the age of respondents within the analyzed groups. The use of 400 mg curcumin per day was statistically significantly improved ultrasound morphological characteristics of the liver in subjects with METS. Conclusion: All respondents with METS who used curcumin had beneficial effects on the morphological characteristics of the liver. Curcumin had stronger effects on subjects with METS and DM type 2 than others.
Objective: analysis and monitoring of the effectiveness of beta-blockers (BB) in the treatment and prognosis of acute coronary syndrome (ACS).Background: Heart and blood vessels disease are the most common chronic disease and the leading cause of death in the world. The largest proportion of deaths from cardiovascular disease is coronary ischemic disease, which represents a broad spectrum of clinical manifestations starting from acute coronary syndrome until stable coronary heart disease, various forms of angina pectoris, chronic myocardial infarction, valvular disease, and eventually heart failure. ACS is a manifestation of atherosclerosis which is usually preceded by acute thrombosis caused by ruptured or eroded atherosclerotic plaque, with or without accompanying vasoconstriction, causing a sudden and critical reduction in blood flow. Patients with ACS, especially older ones, are at high risk of death. Beta-blockers (BB) are drugs that are recommended for early use of ACS in acute myocardial infarction (AMI), and for long-term use in the secondary prevention after AMI, unless there is a contraindication. Early therapy BB is recommended as part of a doubt for the emergency treatment of AMI, especially if the patient with tachycardia or hypertensive. Also, analysis and monitoring of patients in acute myocardial infarction who were subjected to emergency primary coronary intervention (PCI) pointed to the significant reduction in mortality if BB administered to patients before the intervention.Sustained use BB recommended in patients with reduced LVEF after AMI, and in patients with chronic heart failure NYHA II-IV. Early use of BB in the treatment of ACS in our case, together with antiplatelet medication-administration in the prehospital setting, improve the prognosis of stabilization of tachycardia, hypertension, chest pain and reducing the possible "abort"of ECG diagnosed myocardial infarction, and their application in permanent treatment, has shown a significant efficacy in reducing the complications of ACS. Conclusion: The use of BB, unless contraindicated, should begin in the early stages in most patients with ACS, intravenously or orally. The use of BB is particularly justified in tachyarrhythmias and high blood pressure in the ACS, and as adjunctive therapy for the relief of angina attacks. Secondary prevention using hygienic dietary regimen and medical therapy BB, with maximum control of all risk factors improves prognosis and reduces the complications of ACS.
Objective: Analysis of application of contemporary therapeutic modalities in patients with ischemic heart disease (IHD).Background: Acute Coronary Syndrome (Acs) Is One Of A Number Of Syndromes In A Range Of Clinical Manifestations Of Atherosclerosis Of The Coronary Arteries Or Ischemic Heart Disease, Along With Other Clinical Manifestations Such As Angina Pectoris, Chronic Myocardial Infarction, Valvular Disease, And Eventually Cardiac Failure. Access to the management of ischemic heart disease depending on symptoms, functional and anatomical complexity, includes a variety of therapeutic modalities beginning from medical treatment until emergent treatment using percutaneous coronary interventions or aortocoronary bypass surgery. All patients with ischemic heart disease, for the prevention of disease progression and recurrence of cardiovascular events, should be managed by Guideline directed medical therapy (GDMT). The most important groups of drugs are anti-ischemic drugs, antithrombotic (antiplatelet) drugs, anticoagulants and statins. Even revascularization is indicated in patients with IHD and progressive or refractory symptoms, regardless of the management of medicament. In our patient after admission and during hospitalization there was no progression of symptoms. Abrupt cessation and pain relief, rapid return of ST-segment according to the isoelectric line, with optimal pharmacotherapeutic management led to the stabilization of the patient. If there is an occlusion of the coronary artery, the most important is to establish reperfusion as soon as possible. In our patient reperfusion assessment is determined really fast (coronary angiography), and according to the TIMI (Thrombolysis In Myocardial Infarction) levels are classified in the TIMI 2 (there was no thrombotic occlusion of coronary arteries and a partial reperfusion is established). Despite the fact that percutaneous coronary intervention (PCI) is the method of choice in the treatment of ACS, positive effect of antiischemic drug therapy in our patients influenced the decision to cancel the emergency treatment and continue the treatment only by using medical therapy.Conclusion: The initial therapeutic approach by GDMT (Guideline directed medical therapy) for patients with ischemic heart disease (IHD) reduces the progression of atherosclerosis and prevent coronary thrombosis. In patients with ischemia, routine revascularization (with percutaneous coronary intervention or coronary artery bypass graft surgery) plus GDMT improve prognosis and reduce complications and improve quality of life compared to treatment only by using GDMT. The optimal drug therapy, primary and secondary prevention of IHD by the European Society of Cardiology (ESC) guidelines have almost thesame prognostic significance as revascularization
Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo
Saznaj više